REVIEW LEDGER
论文复核台
集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。
| 论文 | 元数据入排 | 图像/No. at risk 复核 | 依据 |
|---|---|---|---|
| Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.PMID 41160818 · 2026-Feb-05 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer.PMID 41324553 · 2026-Feb-04 | needs_reviewThe record describes a study that develops a predictive model using data from two Phase III randomized trials (COU-AA-302 and A031201), but it is not the original formal result report of either trial. The title and abstract focus on model development and validation, not on reporting the primary efficacy results of a drug-containing intervention. The drug intervention is not explicitly named or evaluated in the abstract. | pending- | The record describes a study that develops a predictive model using data from two Phase III randomized trials (COU-AA-302 and A031201), but it is not the original formal result report of either trial. The title and abstract focus on model development and validation, not on reporting the primary efficacy results of a drug-containing intervention. The drug intervention is not explicitly named or evaluated in the abstract. |
| Overall survival with abemaciclib in early breast cancer.PMID 41110697 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).PMID 41110701 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.PMID 41115468 · 2026-Feb | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.PMID 41115469 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.PMID 41125211 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671.PMID 41203001 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.PMID 41253648 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.PMID 41354044 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.PMID 41392465 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.PMID 41519141 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.PMID 41520567 · 2026-Feb | needs_reviewThe record is from a Phase III randomized trial (SHAPE) in oncology with human patients and time-to-event endpoints (RFS, OS) and original results (HR, 3-year rates). However, the intervention is surgical (simple vs radical hysterectomy), not a drug-containing intervention. Therefore, it does not meet the core inclusion criterion of a drug-containing intervention. | pending- | The record is from a Phase III randomized trial (SHAPE) in oncology with human patients and time-to-event endpoints (RFS, OS) and original results (HR, 3-year rates). However, the intervention is surgical (simple vs radical hysterectomy), not a drug-containing intervention. Therefore, it does not meet the core inclusion criterion of a drug-containing intervention. |
| Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.PMID 41526614 · 2026-Feb | needs_reviewThe record is an exploratory analysis of a Phase III randomized trial (IMerge) in oncology with a drug intervention. It is not eligible because it does not present a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) as a formal result; instead, it presents secondary biomarker and response-duration correlations. The original primary trial result is referenced but not reported in this abstract. | pending- | The record is an exploratory analysis of a Phase III randomized trial (IMerge) in oncology with a drug intervention. It is not eligible because it does not present a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) as a formal result; instead, it presents secondary biomarker and response-duration correlations. The original primary trial result is referenced but not reported in this abstract. |
| Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).PMID 41526617 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.PMID 41539318 · 2026-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.PMID 41604639 · 2026-Jan-29 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.PMID 41056515 · 2026-Jan-27 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.PMID 41448222 · 2026-Jan-24 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.PMID 41060326 · 2026-Jan-22 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Nivolumab for Resected Stage III or IV Melanoma at 9 Years.PMID 41124198 · 2026-Jan-22 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.PMID 41564397 · 2026-Jan-22 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.PMID 41365333 · 2026-Jan-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.PMID 41370738 · 2026-Jan-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years.PMID 41535287 · 2026-Jan-14 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.PMID 41521262 · 2026-Jan-12 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.PMID 41337696 · 2026-Jan-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.PMID 41360064 · 2026-Jan-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.PMID 41371238 · 2026-Jan-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.PMID 41391462 · 2026-Jan-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP05 Trial.PMID 40235447 · 2026-Jan-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.PMID 40820816 · 2026-Jan-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.PMID 41104938 · 2026-Jan-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.PMID 41124220 · 2026-Jan-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.PMID 41420831 · 2026-Jan-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.PMID 40998092 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.PMID 41082703 · 2026-Jan | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).PMID 41110692 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.PMID 41110693 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.PMID 41115255 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Clinical Performance of Tissue- and Plasma-Based Diagnostic Assays in Identifying Homologous Recombination Repair Gene Alterations in Patients with Metastatic Castration-Resistant Prostate Cancer following Treatment with Niraparib with Abiraterone Acetate Plus Prednisone (Niraparib + AAP).PMID 41167302 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Combining cell-free DNA fragmentomes and total tumour volume improves prognostication and tumour response evaluation in patients with colorectal cancer liver metastases.PMID 41406506 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study.PMID 41421034 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.PMID 41449142 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.PMID 41449145 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.PMID 41449147 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.PMID 41449150 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.PMID 41482527 · 2026-Jan | needs_reviewThe record describes a Phase III randomized trial in oncology with a drug intervention. However, the abstract does not explicitly report any primary or key secondary time-to-event efficacy results (e.g., overall survival, progression-free survival, hazard ratios, Kaplan-Meier curves, or specific outcome data). It focuses on biomarker and resistance mechanism analysis within the trial. Therefore, eligibility cannot be confirmed based on the provided metadata. | pending- | The record describes a Phase III randomized trial in oncology with a drug intervention. However, the abstract does not explicitly report any primary or key secondary time-to-event efficacy results (e.g., overall survival, progression-free survival, hazard ratios, Kaplan-Meier curves, or specific outcome data). It focuses on biomarker and resistance mechanism analysis within the trial. Therefore, eligibility cannot be confirmed based on the provided metadata. |
| First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.PMID 41494216 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.PMID 41507539 · 2026-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |